NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 66.0 percent, Removing co-finance rate from projects in portugal) |
(Removed claim: budget (P474): 891,220.51 euro) |
||||||
| Property / budget | |||||||
| |||||||
| Property / budget: 891,220.51 Euro / rank | |||||||
Revision as of 06:40, 22 October 2021
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references